Having a large clinical trial portfolio means giving patients treatment options often not available anywhere else, and years before they become the standard of care. To learn more about Karmanos Cancer Institute clinical trials or to see if a trial is right for you, please call 1-800-KARMANOS (1-800-527-6266) or request an appointment below
  • Phase I, Open-label study to evaluate safety, tolerability and preliminary efficacy of modified Salmonella typhimurium SGN1 in Patients with Advanced Solid Tumor

    Cancer Categories
    • Breast,Gastrointestinal (GI),Gynecologic,Head and Neck,Lung,Skin
    Karmanos Trial ID
    • 2021-073
    NCT ID
    • NCT05038150
    Age Group
    • Adult
    • National
    PhaseClick for Clinical Trial Phase DefinitionPhase I
    Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
    • Phase I
    Principal Investigator


    Primary Objectives:

    • To evaluate the safety and tolerability of SGN1 in patients with advanced solid tumor.

    Secondary Objectives:

    • To make a preliminary determination of the Maximum Tolerated Dose (MTD) and optimal biological dose (OBD).
    • To evaluate blood and urine levels of SGN1.
    • To evaluate bacterial shedding of SGN1.
    • To evaluate the anti-tumor effect of SGN1 in the treatment of patients with advanced solid tumor.
    • To evaluate additional safety measures.
  • Locations


    Karmanos Cancer Institute - Detroit Headquarters

    4100 John R
    Detroit, MI 48201
    Get Directions
    Phone: 800-527-6266

    Karmanos Cancer Institute at Weisberg Cancer Center - Farmington Hills

    31995 Northwestern Hwy
    Farmington Hills, MI 48334
    Get Directions
    Phone: 800-527-6266